Wu Dong-Bo, Chen En-Qiang, Tang Hong
Center of Infectious Diseases, West China Hospital of Sichuan University, Sichuan 610041, Chengdu Province, China.
World J Hepatol. 2018 Dec 27;10(12):907-910. doi: 10.4254/wjh.v10.i12.907.
The past two decades have witnessed an explosion of research and clinical application of stem cells, transforming the field of regenerative medicine. Stem cell transplantation has already been performed to treat patients with cancer, liver diseases, and various types of chronic diseases. Indeed, stem cell-based therapies are effective in many diseases, and provide novel insights into the treatment of end-stage liver disease. Several clinical trials have indicated the efficacy profiles of stem cell transplantation in patients with end-stage liver disease, including liver cirrhosis, liver failure, and liver tumors. Animal models of acute liver failure have also provided important insights into the safety, mechanisms, and efficacy of stem cell therapies. Nevertheless, excitement due to this promising field must be tempered with careful and calculated research. In particular, studies on the quality, safety, and efficacy of stem cell transplantation are needed to ensure that qualified products are tested in well-designed clinical trials and approved by governments. Therefore, further investigations are required to effectively balance the safety with the innovation of stem cell transplantation research toward the effective treatment of end-stage liver disease.
在过去二十年中,干细胞的研究和临床应用呈爆发式增长,彻底改变了再生医学领域。干细胞移植已用于治疗癌症、肝脏疾病及各类慢性疾病患者。事实上,基于干细胞的疗法在许多疾病中都很有效,为终末期肝病的治疗提供了新的思路。多项临床试验表明了干细胞移植在终末期肝病患者(包括肝硬化、肝衰竭和肝肿瘤患者)中的疗效。急性肝衰竭的动物模型也为干细胞疗法的安全性、作用机制和疗效提供了重要见解。然而,对于这个前景广阔的领域,我们在兴奋之余,必须进行谨慎且经过深思熟虑的研究。特别是,需要对干细胞移植的质量、安全性和疗效进行研究,以确保在精心设计的临床试验中测试合格产品,并获得政府批准。因此,需要进一步研究,以有效平衡干细胞移植研究的安全性与创新性,从而有效治疗终末期肝病。